Citation Impact
Citing Papers
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
2006 StandoutNobel
Neutralizing antibody response during acute and chronic hepatitis C virus infection
2004 StandoutNobel
Vaccine-delivered HIV envelope inhibits CD4+ T-cell activation, a mechanism for poor HIV vaccine responses
2006 StandoutNobel
Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients
2007 StandoutNobel
Evidence for a functional RNA element in the hepatitis C virus core gene
2007 StandoutNobel
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis
2016 StandoutNobel
Pharmacokinetics and Pharmacodynamics of IFN-β1a in Healthy Volunteers
2000
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
Cancer statistics, 2018
2018 Standout
The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates
1996 Standout
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
Nonstructural protein 3‐4A: the Swiss army knife of hepatitis C virus
2011
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
2009 StandoutNature
Hepatocellular carcinoma
2018 Standout
Multi-input chemical control of protein dimerization for programming graded cellular responses
2019 StandoutNobel
Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir
2007
Liver cirrhosis
2014
Unconventional miR-122 binding stabilizes the HCV genome by forming a trimolecular RNA structure
2013 StandoutNobel
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
2012
Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives
1997
Core Structure of gp41 from the HIV Envelope Glycoprotein
1997 Standout
The role of resistance in HCV treatment
2012
Metazoan MicroRNAs
2018 Standout
Interleukin-17 and Type 17 Helper T Cells
2009 Standout
Antiviral strategies in hepatitis C virus infection
2012
Protease Inhibitor–Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious Virus
2010
Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin
2015 StandoutNobel
Axonal Transection in the Lesions of Multiple Sclerosis
1998 Standout
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
2011
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice
2010
Argonaute CLIP Defines a Deregulated miR-122-Bound Transcriptome that Correlates with Patient Survival in Human Liver Cancer
2017 StandoutNobel
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
A diverse range of gene products are effectors of the type I interferon antiviral response
2011 StandoutNatureNobel
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
2011
Immunomodulatory functions of type I interferons
2012
Multiple Sclerosis
2000 Standout
A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication
2009
SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders
2007
A Functional Genomic Screen Identifies Cellular Cofactors of Hepatitis C Virus Replication
2009
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
HIV fusion and its inhibition
2001
Interferon β-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study
2003
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
2017 Standout
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
2004 Standout
Treatment of HCV Infection by Targeting MicroRNA
2013 Standout
Multiple sclerosis
2002 Standout
Current race in the development of DAAs (direct-acting antivirals) against HCV
2014
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
2020 Standout
Hepatitis C Virus RNA Functionally Sequesters miR-122
2015 StandoutNobel
Mechanisms of action of glatiramer acetate in multiple sclerosis
2001
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
2003 StandoutNobel
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
1998 Standout
Treatment of Hepatitis C
2014
Decreased Stimulation of CD4+ T Cell Proliferation and IL-2 Production by Highly Enriched Populations of HIV-Infected Dendritic Cells
2003
Dendritic-cell maturation alters intracellular signaling networks, enabling differential effects of IFN-α/β on antigen cross-presentation
2006 StandoutNobel
Characterization of nonprimate hepacivirus and construction of a functional molecular clone
2015 StandoutNobel
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Modeling hepatitis C virus infection using human induced pluripotent stem cells
2012 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis
1999
A bacterial Argonaute with noncanonical guide RNA specificity
2016 StandoutNobel
Development of an Intergenotypic Hepatitis C Virus (HCV) Cell Culture Method To Assess Antiviral Susceptibilities and Resistance Development of HCV NS3 Protease Genes from HCV Genotypes 1 to 6
2010
Interferon-Stimulated Genes: A Complex Web of Host Defenses
2014 StandoutNobel
Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity
2001
Cellular cofactors affecting hepatitis C virus infection and replication
2007 StandoutNobel
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs
2002 StandoutNobel
Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta‐1a after intramuscular and subcutaneous administration
1998
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle
2010 StandoutNobel
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders
2005 StandoutNobel
Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796
2008
Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics
2016
HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation
2004 StandoutNobel
Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity
2001
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.
2012
Novel Therapies for Hepatitis C: Insights from the Structure of the Virus
2011
Prospects for the Future
2002 StandoutScienceNobel
Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
1995
Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]
2002
Works of John Alam being referenced
Comparative Pharmacokinetics and Pharmacodynamics of Two Recomhinant Human Interferon Beta-la (IFNβ-la) Products Administered Intramuscularly in Healthy Male and Female Volunteers
1997
Interferon beta induces interleukin‐10 expression: Relevance to multiple sclerosis
1996
The Effects of High-Dose Recombinant Soluble CD4 on Human Immunodeficiency Virus Type 1 Viremia
1994
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
2009
Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study
2006
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
2009
Pharmacokinetics and Pharmacodynamics of Interferon Beta-1a (IFN??-1a) in Healthy Volunteers after Intravenous, Subcutaneous or Intramuscular Administration
1997
Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats
2015
Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection.
1995